Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bupivacaine Liposome Injection
NCT07279155Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of bupivacaine liposome in postoperative pain (2 arms), sponsored by Hengrui. Primary endpoints: Maximum plasma concentration, Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration and 1 more. Started Jun 2025; status: completed.
02
Drugs
bupivacaine liposome
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT07279155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279155.